These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 1363891)
1. [Cancer of the breast]. Maugard-Louboutin C Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):949-55. PubMed ID: 1363891 [TBL] [Abstract][Full Text] [Related]
2. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965 [TBL] [Abstract][Full Text] [Related]
3. Hormonal approaches to breast cancer treatment and prevention: an overview. Vogel CL Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey. Paridaens R Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U; Wilke H; Seeber S Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897 [TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894 [TBL] [Abstract][Full Text] [Related]
7. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656 [TBL] [Abstract][Full Text] [Related]
8. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Holmes FA Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900 [TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and doxorubicin in metastatic breast cancer. Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524 [TBL] [Abstract][Full Text] [Related]
13. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090 [TBL] [Abstract][Full Text] [Related]
15. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034 [TBL] [Abstract][Full Text] [Related]
16. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group. Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921 [TBL] [Abstract][Full Text] [Related]
18. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Holmes FA Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Buzdar AU; Holmes FA; Hortobagyi GN Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]